ИЗУЧЕНИЕ КАЧЕСТВАЖИЗНИ БОЛЬНЫХ С ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ
Аннотация
Изучение качества жизни больных с хронической сердечной недостаточностью: современное состояние проблемы.
Об авторах
С. Р. Гиляревский
Российская медицинская академия последипломного образования
Россия
Россия
Кафедра клинической фармакологии
В. А. Орлов
Российская медицинская академия последипломного образования
Россия
Россия
Кафедра клинической фармакологии
зав. кафедрой - проф.
Н. Г. Бенделиани
Российская медицинская академия последипломного образования
Россия
Россия
Кафедра клинической фармакологии
Л. К. Хамаганова
Российская медицинская академия последипломного образования
Россия
Россия
Кафедра клинической фармакологии
Е. Ю. Сычева
Российская медицинская академия последипломного образования
Россия
Россия
Кафедра клинической фармакологии
Список литературы
1. Albanese MC, Plewka M, Gregori D, Fresco C, Avon G, Caliandro D, Grassi L, Rossi P, Udina P, Bulfoni A, Colle R, Cuzzato AL, Fioretti PM. Use of medical resources and quality of life of patients with chronic heart failure: a prospective survey in a large Italian community hospital. Eur J Heart Failure. 1999; 1(4): 411-417
2. O’Driscoll G Chronic heart failure. A guide for practical management. Aust Fam Physician 2000; 29(5):423-7
3. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429-1435
4. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302
5. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303- 310
6. Patterson JA, Naughton J, Pietras RJ. Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol 1972; 30; 757-762
7. Wenger NK. Quality of life: can it and should it be assessed in patients with chronic heart failure. Cardiology 1989; 76: 391-398
8. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States 1973-1986: evidence for screening population prevalence. Arch Intern Med 1992; 150: 769-73
9. Murray MD, Bennett SJ, Ferguson JA, Adams LD, Forthofer MM, Minick SM, Brater D C, Tierney WM. Improved health-related quality of life for heart failure by using a completely and predictably absorbed loop diuretic. J Gen Int Med. 1998; 13(suppl.1): 19
10. Cohn JN Improving outcomes in congestive heart failure: ValHeFT. Valsartan in Heart Failure Trial. Cardiology 1999; 91 Suppl 1: 19-22
11. Cohen-Solal A, Bouhour JB, Thebaut JF.The management of patients with heart failure in France. Eur J Heart Fail 2000: 2(2): 223-226
12. Glaser A., Walker D. Quality of life. Lancet. 1995; 346: 444
13. Muldoon MF, SD Barger, Flory JD, Manuck SB. What are quality of life measurements measuring? BMJ 1998;316:542-545
14. Spilker B, Molinek FR Jr, Johnson KA. Quality of life bibliography and indexes. Med Care. 1990; 28(suppl.): 1-77
15. Skevington SM. Measuring quality of life in Britain: introducing the WHOQOL-100. J Psychosomatic Res. 1999; 47(5): 449-459
16. Green CP, Porter CB, Bresnahan DR, Spertus JA Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35(5):1245-55
17. Patrick DL, Bergner M. Measurement of health status in the 1990s. Ann Rev Public Health 1990; 11: 165-183
18. Guyatt G, Feeny D, Patrick D. Issues in quality of life measurement in clinical trials. Control Clin Trials 1991; 12: 81-90S.
19. Boer JB, Dam FSAMV, Sprangers MAG. Health-ralated quality of life evaluation in HIV-infected patients. Pharmacoeconomics. 1995; 8(4): 291-304
20. Gandhi SK, Kong SX. Quality of life measures in the evaluation of antihypertensive drug therapy: reliability, validity, and quality of life domains. Clin.Ther. 1996; 18: 1276-1295
21. Midgley DE, Bradlee TA, Donohoe C, Kent KP, Alonso EM Health-related quality of life in long-term survivors of pediatric liver transplantation. Liver Transpl 2000 May;6(3):333-9
22. Cleland JGF, Clark A. Has the survival of the heart failure population changed? lessons from trials. Am J Cardiol. 1999; 83(5B): 112-119
23. Daubert JC, Cazeau S, Leclercq C. Do we have reasons to be enthusiastic about pacing to treat advanced heart failure? Eur.J.Heart Failure. 1999; 1(3): 281-287
24. Winters CA. Heart failure: living with uncertainty. Prog Cardiovasc Nurs 1999; 14(3): 85-91
25. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJS. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997; 349 (9058): 1050-1053
26. Packer M, Carver JR, Rodeheffer RJ, et al., for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468–75.
27. Cowley AJ, Skene AM, on behalf of the Enoximone Investigators. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J 1994;72:226–30.
28. Krell MJ, Kline EM and Bates ER et al. Intermittent, ambulatory dobutamine infusion in patients with severe congestive heart failure. Am Heart J 1986, 112:787-791.
29. Hampton JR, van Veldhuisen DJ, Kleber FX. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet. 1997; 349: 971-977
30. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure.The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994; 90: 1765-1773
31. Metra M., Nardi M., Giubbini R., Dei Cas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical onditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994; 24: 1678-1687
32. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995; 25: 1225-1231
33. Doughty RN. Beta-blockers for advanced heart failure — how far can you go? Eur J Heart Failure. 1999; 1(3): 259-262
34. Australia-New Zeland Heart Failure Research Collaborative Group. Ffects of carvedilol, a vasodilator beta-blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation. 1995; 92: 212-218
35. Feenstra J, Lubsen J, Grobbee DF, Stricker BH. Heart failure treatments: issues of safety versus issues of quality of life. Drug Saf 1999; 1: 1-7
36. Berry C, McMurray J A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics 1999 Sep;16(3):247-71
37. Jaarsma T., Halfens R., Huijer Abu-Saad H., Dracup K., Stappers J., van Ree J. Quality of life in older patients with systolic and diastolic heart failure Eur J Heart Failure. 1999; 1(2): 151- 160
38. Brown J, Klapow J, Doleys D, Lowery D, Tutak U Diseasespecific and generic health outcomes: a model for the evaluation of long-term intrathecal opioid therapy in noncancer low back pain patients. Clin J Pain 1999 Jun;15(2):122-31
39. Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thorson AG, Wexner SD, Bliss D, Lowry AC. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum 2000 Jan;43(1):9-16; discussion 16-7
40. Coons SJ, Rao S, Keininger DL, Hays RD A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000;17(1): 13-35
41. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51(11): 903-12
42. Ware JE Jr, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M, Thunedborg K The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51(11): 1167- 70
43. Quittan M, Sturm B, Wiesinger GF, Pacher R, Fialka-Moser V Quality of life in patients with chronic heart failure: a randomized controlled trial of changes induced by a regular exercise program. Scand J Rehabil Med 1999; 31(4): 223-8
44. Chin MH; Goldman L. Gender differences in 1-year survival and quality of life among patients admitted with congestive heart failure. Med Care 1998; 36(7): 1033-46 45 Blyth FM, Lazarus R, Ross D, Price M, Cheuk G, Leeder SR. Burden and outcomes of hospitalisation for congestive heart failure. Med J Aust 1997; 167(2): 67-70
45. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: Development and final revision of a health status measure. Medical Care 1981; 19: 787-805
46. Bulpitt CJ Quality of life with ACE inhibitors in chronic heart failure. J Cardiovasc Pharmacol 1996; 27 Suppl 2: S31-5
47. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS The sickness impact profile: validation of a health status measure. Med Care 1976; 14(1): 57-67
48. de Bruin AF, de Witte LP, Stevens F, Diederiks JP Sickness Impact Profile: the state of the art of a generic functional status measure. Soc Sci Med 1992; 35(8): 1003-14
49. Cline CM, Willenheimer RB, Erhardt LR, Wiklund I, Israelsson BY Health-related quality of life in elderly patients with heart failure. Scand Cardiovasc J 1999;33(5):278-85
50. Jones BM, Taylor F, Downs K, Spratt P Longitudinal study of quality of life and psychological adjustment after cardiac transplantation. Med J Aust 1992 6;157(1):24-6
51. Lukkarinen HRN, Hentinen M. Assessment of quality of life with the Nottingham Health Profile among women with coronary artery disease. Heart & Lung The Journal of Acute and Critical Care 1998; 27(3): 189-199
52. Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillation. New York Heart Association. Am Heart J 1998; 135(5 Pt 1): 819-24
53. Sevick MA, Magovern J, Kamlet MS, Rawson I, McCall M, Locke C Health-related physical function and quality of well-being prior to and following cardiomyoplasty. A preliminary report. Panminerva Med 1998; 40(1): 8-12
54. Van Weel C. Functional status in primary care: COOP/WONCA charts. Disabil Rehabil 1993; 15(2): 96-101
55. McBride JL, Pilkington L, Arthur G. Development of brief pictorial instruments for assessing spirituality in primary care. J Ambulatory Care Manage 1998; 21(4): 53-61
56. Wasson JH, Kairys SW, Nelson EC, Kalishman N, Baribeau P A short survey for assessing health and social problems of adolescents. Dartmouth Primary Care Cooperative Information Project (The COOP). J Fam Pract 1994; 38(5): 489-94
57. Jenkinson C, Jenkinson D, Shepperd S, Layte R, Petersen S. Evaluation of treatment for congestive heart failure in patients aged 60 years and older using generic measures of health status (SF-36 and COOP charts). Age Ageing 1997; 26(1): 7-13
58. Neumann PJ, Zinner DE, Wright JC Are methods for estimating QALYs in cost-effectiveness analyses improving? Med Decis Making 1997; 17(4): 402-8
59. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15(2): 141-55
60. Roset M, Badia X, Mayo NE. Sample size calculations in studies using the EuroQol 5D. Qual Life Res 1999; 8(6): 539-49
61. Недошивин АО, Петрова НН, Кутузова АЕ, Перепеч НБ. Влияние милдроната на качество жизни больных с хронической сердечной недостаточностью. Тер.архив 1999; 71(8): 10-1
62. Rector TS, Ormaza SM, Kubo SH Health status of heart transplant recipients versus patients awaiting heart transplantation: a preliminary evaluation of the SF-36 questionnaire. J Heart Lung Transplant 1993; 12(6): 983-6
63. Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clin Rheumatol 2000;19(3):195- 9
64. Lyons RA, Lo SV, Littlepage BN Comparative health status of patients with 11 common illnesses in Wales. J Epidemiol Community Health 1994; 48(4): 388-90
65. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998;317:1191-1194
66. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF 36): conceptual framework and item selection. Med Care 1992; 30: 473-485
67. Stansfeld SA, Roberts R, Foot SP Assessing the validity of the SF-36 General Health Survey. Qual Life Res 1997; 6(3): 217-24
68. Keller SD, Ware JE Jr, Bentler PM, Aaronson NK, Alonso J, Apolone G, Bjorner JB, Brazier J, Bullinger M, Kaasa S, Leplege A, Sullivan M, Gandek B. Use of structural equation modeling to test the construct validity of the SF-36 Health Survey in ten countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998 Nov;51(11):1179-88
69. Jenkinson C, Coulter A, Wright L. Short form 36 (SF 36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306: 1437-1440
70. Brazier JE, Harper R, Jones NMB. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160-164
71. Edelman D, Williams GR, Rothman M, Samsa GP A comparison of three health status measures in primary care outpatients. J Gen Intern Med 1999; 14(12): 759-62
72. Perneger TV, Leplege A, Guillain H, Ecosse E, Etter JF COOP Charts in French: translation and preliminary data on instrument properties. Qual Life Res 1998; 7(8): 683-92
73. Schrag A, Selai C, Jahanshahi M, Quinn NP The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000 Jul;69(1):67-73
74. Leplege A, Ecosse E, Verdier A, Perneger TV. The French SF- 36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998; 51(11): 1013-23
75. Apolone G, Mosconi P. The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 1998; 51(11): 1025-36
76. Alonso J, Regidor E, Barrio G, Prieto L, Rodriguez C, de la Fuente L. Population reference values of the Spanish version of the Health Questionnaire SF-36. Med Clin (Barc) 1998; 111(11): 410-6
77. Bjorner JB, Thunedborg K, Kristensen TS, Modvig J, Bech P The Danish SF-36 Health Survey: translation and preliminary validity studies. J Clin Epidemiol 1998; 51(11): 991-9
78. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51(11): 1045-53
79. Lam CL, Gandek B, Ren XS, Chan MS Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 Health Survey. J Clin Epidemiol 1998; 51(11): 1139- 47
80. Garratt AM, Ruta DA, Abdalla MI. The SF 36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993; 306: 1440-1444
81. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction o scales and preliminary tests of reliability and validity. Med Care 1995; 34; 220-233
82. Ni H, Nauman DJ, Burgess D. Comparison of SF-12 and Minnesota Living with Heart Failure Questionnaire regarding their sensitivities to the effect of program interventions on restoring quality of life [abstract 212]. Heart Failure Soc 1998; 212: 13-16
83. Rogers WJ, Johnstone DE, Yusuf S, Quality of life among 5025 patients with left ventricular dysfunction randomized between placebo and enalapril: the studies of left ventricular dysfunction. J Am Coll Cardiol 1994; 23: 393-400
84. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 1980; 34(4): 281- 6
85. Mitchell RA, Imperial E, Kelleher P, Brunker P, Gass G Perceived health problems in subjects with varying cardiovascular diagnoses. J Behav Med 1991 Oct;14(5):505-12
86. Marwick TH, Zuchowski C, Lauer MS, Secknus MA, Williams J, Lytle BW Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol 1999; 33(3): 750-8
87. Ekeberg O, Klemsdal TO, Kjeldsen SE. Quality of life on enalapril after acute myocardial infarction. Eur Heart J 1994; 15(8): 1135-1139
88. Harwood R. Quality of life in heart failure treated with enoximone [letter]. Br Heart J 1994; 72: 584
89. Kohlmann T, Bullinger M, Kirchberger-Blumstein I German version of the Nottingham Health Profile (NHP): translation and psychometric validation. Soz Praventivmed 1997;42(3):175-85
90. Pouchot J, Guillemin F, Coste J, Bregeon C, Sany J Validation of the French version of the arthritis impact measurement scales 2 and comparison with the french version of the Nottingham Health Profile. «Quality of Life in Rheumatology» Task Force. Rev Rhum Engl Ed 1996; 63(6): 389-404
91. Prieto L, Alonso J, Viladrich MC, Anto JM Scaling the Spanish version of the Nottingham Health Profile: evidence of limited value of item weights. J Clin Epidemiol 1996;49(1):31-8
92. Kucukdeveci AA, McKenna SP, Kutlay S, Gursel Y, Whalley D, Arasil T The development and psychometric assessment of the Turkish version of the Nottingham Health Profile. Int J Rehabil Res 2000; 23(1): 31-8
93. Гиляревский С.Р., Орлов В.А. Оценка качества жизни больных ревматическими митральными пороками сердца: методические подходы. Кардиология 1992; 32(6): 49-53
94. Bergener M, Bobbitt RA, Carter WB. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805
95. Rector TS, Francis GS, Cohn JN. Patient’s self-assessment of their congestive heart failure. Heart Fail 1987; 3: 198-209
96. Rector TS. Usefullness of OPC-8212, a quinolone derivative, for chronic congestive heart failure in patients with ischaemic heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68(11): 1203-1210
97. Bulpitt CJ, Fletcher AE, Dossenger L. Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Heart 1998; 79: 593-598
98. Anderson JP, Kaplan RM, Berry CC. Interday reliability of function assessment for a health status measure: the Quality of well-being scale. Med Care 1989; 27: 1076-1084
99. Tandon PK, Stander H, Dyke SH. Assessment of quality of life of patients with heart failure: a randomized, controlled drug trial. Heart Fail 1988; 4: 39-54
100. Cantril H. The pattern of human concerns. New Brunswick, NJ: Rutgers University Press, 1965.
101. Philbin EF, Rocco TA Jr., Lindenmuth NW, Ulrich K, Jenkins PL.Clinical outcomes in heart failure: report from a community hospital-based registry. Am J Med. 1999; 107(6): 549-555
102. Senten CMS. The well being of patients having CAB surgery: a test of Orem’s self-care nursing theory [dissertation]. University of Limburg, Maastricht, 1991.
103. The Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels; nomenclature and criteria for diagnosis. 6th ed. Boston: Little, Brown, 1964.
104. Harvey RM, Doyle EF, Ellis K, et al. Major changes made by the Criteria Committee of the New York Heart Association. Circulation 1974;49:390.
105. Goldman L. Classification systems for the serial assessment of cardiac functional status. Pract.Cardiol. 1983; 9(4): 40-57
106. Goldman L, Hashimoto B, Cook E, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981; 64(6): 1227-1234
107. Hlatky MA, Boineau RE, Higginbotham MB. A brief selfadministrated questionnaire to determine functional capacity (The Duke Activity Status Index). Am J Cardiol. 1989; 64: 651-654
108. Hamilton DM, Haennel RG Validity and reliability of the 6- minute walk test in a cardiac rehabilitation population. J Cardiopulm Rehabil 2000; 20(3): 156-64
109. Williams E., Klesges RC, Hanson CL, Eck LN. A prospective study of the reliability and convergent validity of three physical activity measures in a field research trial. J Clin Epidemiol. 1989; 42(13): 1161-1170
110. Gibelin P, Aumont M-C, Aupetit J-F, Bareiss P, Bouhour JB, Desnos M, Dubourg O, Hagege A, Jondeau G, Komajda M. Evaluation d’une echelle d’activite specifique francaise de l’insuffisance cardiaque chronique. Etude multicentrique nationale. Archives des Maladies du Coeur et des Vaisseaux (France) 1999; 92(9): 1175-1180
111. Rector TS, Tschumperlin LK, Kubo SH, Bank AJ, Francis GS, McDonald KM, Keeler CA, Silver MA Use of the Living With Heart Failure questionnaire to ascertain patients’ perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail 1995; 1(3): 201-6
112. Klaus L, Beniaminovitz A, Choi L, Greenfield F, Whitworth GC, Oz MC, Mancini DM. Pilot study of guided imagery use in patients with severe heart failure.Am J Cardiol. 2000; 86(1): 101- 104
113. Auricchio A, Klein H, Spinelli J. Pacing for heart failure: selection of patients, techniques and benefits. Eur J Heart Failure 1999; 1(3): 275-279
114. Ni H, Toy W, Burgess D, Wise K, Nauman DJ, Crispell K, Hershberger RE Comparative responsiveness of Short-Form 12 and Minnesota Living With Heart Failure Questionnaire in patients with heart failure. J Card Fail 2000; 6(2): 83-91
115. Либис РА, Коц ЯИ, Агеев ФТ, Мареев ВЮ. Качество жизни как критерии успешной терапии больных с хроничес- кой сердечной недостаточностью. РМЖ. 2000; 2:
116. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double blind, placebocontrolled trial of pimobendan. A Heart J 1992; 124: 1017-1025
117. Cohn JN, Ziesche S, Smith R. Effect of calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. Circulation 1997; 96: 856-63
118. Wilson JR, Groves J, Rayos G. Circulatory status and response to cardiac rehabilitation in patients with heart failure. Circulation 1996; 94: 567-72
119. Guyatt GH; Nogradi S; Halcrow S; Singer J; Sullivan MJ; Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J General Internal Medicine. 1989; 4(2):101-7.
120. Guyatt GH, Sullivan MJJ, Fallen E. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988; 61: 371-5
121. O’Leary CJ, Jones PW. The left ventricular dysfunction questionnaire (LVD-36): reliability, validity, and responsiveness. Heart 2000; 83(6): 634-40
122. Gundersen T, Wiklund I, Swedberg K, Amtorp O, Remes J, Nilsson B Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Ramipril Study Group. Cardiovasc Drugs Ther 1995 Aug;9(4):589-94
123. Wiklund I, Lindvall K, Swedberg K. Self-assessment of quality of life in severe heart failure. Scand J Psychol 1987; 28: 220-5
124. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
125. Feinstein AR, Fisher M, Pigeon J. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989, 64:50-55
126. Spitzer WO. State of science 1986: Quality of life and functional status as target variables for research. J Chron Dis. 1987; 40(6): 465-471
127. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
128. Mark DB, Simons TA. Fundamentals of economic analysis. Am Heart J. 1999; 137(5): S38-40
129. Investigating Health and Health Services.– Research Methods in Health.– 4.Costing health services: health economics/with Ian Rees Jones.– Buckingham – Philadelphia: Open University Press, 1997.– P.79-98.
130. Palmer S, Byford S, Raftery J.Types of economic evaluation. BMJ 1999; 318: 1349-1349
131. Brown GC; Sharma S; Brown MM; Garrett S. Evidence-based medicine and cost-effectiveness. J Health Care Finance 1999; 26(2): 14-23
132. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960- 1968.
133. Mark DB. Economics of treating heart failure. Am J Cardiol. 1997; 80(8B): 33H-38H.
134. Clark N.M., Gong M. Management of chronic disease by practitioners and patients: are we teaching the wrong things? BMJ 2000; 320: 572-575.
135. Jaarsma T., Halfens R., Huijer Abu-Saad H., Dracup K., Gorgels T., van Ree J., Stappers J. Effects of education and support on self-care and resourse utilization in patients with heart failure. Eur. Heart J. 1999; 20: 673-682
136. Clark NM, Janz NK, Becker MH, Schork MA, Wheeler J, Liang J, Dodge JA, Keteyian S, Rhoads KL, Santinga JT. Impact of self-management education on the functional health status of older adults with heart disease. Gerontologist. 1992; 32(4): 438- 443.
137. Schneider JK, Hornberger S, Booker J, Davis A, Kralicek R. A medication discharge planning program. Clinical Nursing Research. 1993; 2(1): 41-53.
138. Rich MW Vinson JM, Sperry JC, Shah AS, Spinner LR, Chung MK, Davila-Roman V. Prevention of readmission in elderly patients with congestive heart failure. J. Gen. Intern. Med. 1993; 8: 585-590.
139. Goodyer LI, Miskelly F., Milligan P. Does encouraging good compliance improve patients’ clinical condition in heart failure? Br.J.Clin.Pract. 1995; 49(4): 173-176
140. Cline C.M.J., Israelsson B.Y.A., Willenheimer R.B., Broms K., Erhardt L.R. Cost effective management programme for heart failure reduces hospitalisation. Heart 1998; 80: 442-446
141. Gattis WA, Hasselblad V., Whellan DJ, O’Connor CM. Reduction in heart failure events by the addition of a clinicl pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch.Int.Med. 1999; 159(16): 1939- 1945
142. Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health Syst Pharm. 1999; 56(13): 1339-1342
143. Varma S., McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of patients with congestive heart failure: Interventions and outcomes. Pharmacotherapy. 1999; 19(7): 860- 869
144. Rich MW, Beckham V., Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N.Engl.J.Med.1995; 333(18): 1190-1195.
145. Kostis JB, Rosen RC, Cosgrove NM, Shindler DM, Wilson AC. Nonpharmacologic therapy improves functional and emotional status in congestive heart failure. Chest. 1994; 106: 996-1001.
146. VanderZee KI, Sanderman R, Heyink J. A comparison of two multidimensional measures of health status: the Nottingham Health Profile and the RAND 36-Item Health Survey 1.0. Qual Life Res 1996;5(1): 165-74
147. Gaul GB. Quality of life - therapieziel oder schlagwort? Journal fur Kardiologie (Austria) 1999: 6(12): 617-621
148. Rector TS, Johnson G, Dunkman WB. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. Circulation 1993; 87 Suppl.VI: 71-76
149. Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin M. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Circulation 1993, 88:492-501
150. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992;85:942-9
151. Lubsen J, Just H, Hjalmarsson AC. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-231
152. Packer M, Colucci WS, Sackner-Bernstein JD, the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94: 2793-9
153. Wiklund I, Waagstein F, Swedberg K. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Cardiovasc Drugs Ther 1996; 10: 361-8
154. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions. N Engl J Med. 1996; 334(22): 1441-1447
155. Stewart S, Marley JE, Horowitz JD. Effects of multidisciplinary, home-based intervention on planned readmissions and survival among patients with chronic congestive heart failure: a randomized controlled study. Lancet 1999; 354(9184): 1077-1083.
Рецензия
Для цитирования:
Гиляревский С.Р., Орлов В.А., Бенделиани Н.Г., Хамаганова Л.К., Сычева Е.Ю. ИЗУЧЕНИЕ КАЧЕСТВАЖИЗНИ БОЛЬНЫХ С ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ. Российский кардиологический журнал. 2001;(3):58-72.
For citation:
Gilarevsky S.R., Orlov V.A., Bendeliani N.G., Hamaganova L.K., Sycheva E.Y. A STUDY OF LIFE QUALITY IN PATIENTS WITH CHRONIC HEART FAILURE: THE CONTEMPORARY STATUS. Russian Journal of Cardiology. 2001;(3):58-72. (In Russ.)
Просмотров:
572
Послать статью по эл. почте 